Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris).
Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris).
复制标题
对 130 名急性淋巴细胞白血病患者进行联合治疗（方案 06 LA 66-巴黎）。
作者：
C. Jacquillat;M. Weil;M. Gémon;G. Auclerc;J. Loisel;J. Delobel;G. Flandrin;G. Schaison;V. Izrael;A. Bussel;C. Dresch;C. Weisgerber;D. Rain;J. Tanzer;Y. Najean;M. Seligmann;M. Boiron;J. Bernard
130例急性淋巴细胞白血病患者采用06 LA 66方案治疗。采用该方案，较年轻组（100例20岁以下患者）比较年长组（30例20岁以上患者）获得完全缓解的频率更高，女性比男性更频繁。血液学缓解的中位持续时间在年轻组为34个月，在老年组为11个月。15 ~ 20岁患者的预后与老年患者相同；预后根据年龄、初始白细胞计数和达到完全缓解所需的剂量而变化。尽管给予预防性鞘内注射甲氨蝶呤，仍有33%的病例发生脑膜白血病，其中一半的病例在发病的第一年发生脑膜白血病。这些早期脑膜白血病病例中有20%在5年后没有血液学复发，而达到完全缓解的年轻组中有48%存活超过4年。
Summary One hundred thirty patients with acute lymphoblastic leukemia were treated with Protocol 06 LA 66. With this regimen complete remissions were achieved more frequently in the younger group (100 patients under 20 years of age) than in the older group (30 patients over 20 years of age), and in females more frequently than in males. The median duration of hematological remission was 34 months in the younger group and 11 months in the older group. In patients between 15 and 20 years of age, the prognosis was the same as in the older patients; the prognosis varied according to age, the initial white blood cell count, and the number of doses required to achieve complete remission. Meningeal leukemia occurred in 33% of the cases in spite of preventive intrathecal doses of methotrexate, and in onehalf of these cases meningeal leukemia occurred during the first year of the disease. Twenty % of these early meningeal leukemia cases showed no hematological relapse 5 years later, and 48% of the younger group who attained complete remission survived for more than 4 years.